MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

168.60B

Vuru Grade

54.36/100

Current Price

$61.15
-0.66 (-1.07%)

Growth Price

$54.63
Overvalued by 10.67%

Stability Price

$20.59
Overvalued by 66.33%

Company Metrics

  • P/E 31.23
  • P/S 4.27
  • P/B 3.9
  • EPS 1.96
  • Cash ROIC 12.97%
  • Cash Ratio 0.70
  • Dividend 1.88 / 3.01%
  • Avg. Vol. 11.56M
  • Shares 2.76B
  • Market Cap. 168.60B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Better Buy: Merck & Co. Inc. vs. Pfizer
Fox Business - Jan 22, 2017
Merck (NYSE: MRK) and Pfizer (NYSE: PFE) compete against each other in several markets, from cancer to vaccines. The big drugmakers also work together from time to time.
Bristol-Myers Squibb Co (NYSE:BMY) To Share In Sales Of Merck & Co., Inc ... - Market Exclusive
2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016
Motley Fool - Jan 6, 2017
Shares of Merck & Co., Inc. (NYSE:MRK), a U.S.-based global drug behemoth, climbed 11% higher in 2016, according to data from S&P Global Market Intelligence, slightly outpacing the 9.5% return of the S&P 500, and putting the SPDR S&P Pharmaceuticals ...
Why Merck & Co., Inc. (MRK) Stock Is Higher Today
Investorplace.com - Jan 20, 2017
Last week, Merck & Co's Keytruda cancer drug received a swift review from U.S. regulators. The medication is designed to be used along with chemotherapy in order to treat lung cancer, and it is believed that the medication now has great potential to be ...
Bristol-Myers lung cancer delay slams shares, keeps Merck in lead - Yahoo Finance
Bristol's Opdivo Dependence Now Looks Dicey - Bloomberg
Middleton & Co Inc MA Has $10303000 Stake in Merck & Co. (MRK)
Sports Perspectives - 9 hours ago
Merck & Co. logo Middleton & Co Inc MA cut its stake in Merck & Co. (NYSE:MRK) by 2.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission.
Merck & Company Inc. (new) (MRK) Closes 1.15% Down on the Day for January 23 - Equities.com
Oppenheimer & Co. Inc. Sells 35536 Shares of Merck & Co. (MRK) - BBNS
Featured Stock Overview: Merck & Co., Inc. (NYSE:MRK)
FactsReporter - 7 hours ago
Many analysts have provided their estimated foresights on Merck & Co., Inc. Earnings, with 18 analysts believing the company would generate an Average Estimate of $0.89.
Revenue Estimates Analysis of: Merck & Co., Inc. (NYSE:MRK) - News Oracle
Why Merck is a Top Socially Responsible Dividend Stock (MRK)
Forbes - 9 hours ago
Merck & Co Inc (NYSE: MRK) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ”DividendRank” statistics including a strong 3.0% yield, as well as being recognized by prominent asset ...
Merck & Co., Inc. (MRK) Stock Is Defying the Bears!
Investorplace.com - Jan 4, 2017
The first trading day of 2017 was a mixed session. Although the broader indices ended higher on the day, underneath the surface, things traded in a sloppy fashion.
Merck & Company Inc. (new) (MRK) Closes 0.03% Down on the Day for January 05 - Equities.com
Merck & Co., Inc. (NYSE:MRK): Upgraded To Overweight
Smаrt Stоck Nеws - Jan 13, 2017
Merck & Co., Inc. (NYSE:MRK) issued an update highlighting that FDA had accepted a filing based on the KEYNOTE 021G data presented at ESMO comparing Keytruda + chemo vs chemo alone in all PD-L1 sub-groups.
Merck Muscles Into Bristol's Combo Space - Seeking Alpha
US FDA agrees to accelerated review of Merck immunotherapy drug combination ... - Proactive Investors USA & Canada
Option Market: Merck & Co. Inc Risk Hits A Tumbling Low
CML News - 9 hours ago
We're going to look at a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for Merck & Co. Inc (NYSE:MRK) .
Merck & Co., Inc. (NYSE:MRK) Joins Forces With M2Gen To Explore The ORIEN ...
Market Exclusive - Jan 6, 2017
Merck & Co., Inc. (NYSE:MRK), which is popularly known as MSD outside the United States and Canada, has become part of the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program.
Analysts' Recommendations Trending Stocks: Merck & Co., Inc. (NYSE:MRK ... - Money News